PPN20- ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS- RESULTS FROM THE MIMS TRIAL
Abstract
Authors
TL Durgin LA Wanke D Goodkin R Ghalie